Trading

Data

Solutions

Insights

KSQ Therapeutics Stock

ksqtx.comHealthcareFounded: 2015Funding to Date: $257.46MM

KSQ Therapeutics is the developer of a genome-scale precision functional genomics platform, called CRISPRomics, designed to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.

Buy or sell KSQ Therapeutics stock Learn more about KSQ Therapeutics IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for KSQ Therapeutics.

Register Today

Team

Management Team

David Meeker MD

Chief Executive Officer & Board Member

David Sabatini Ph.D

Co-Founder

Jonathan Weissman Ph.D

Co-Founder

John Trzupek Ph.D

Interim Chief Financial Officer & Head, Corporate Development

William Hahn MD

Co-Founder

Frank Stegmeier Ph.D

Chief Scientific Officer

Tim Wang Ph.D

Co-Founder

Board Members

David Meeker MD

George Golumbeski Ph.D

David Berry Ph.D

Flagship Pioneering

Pearl Huang Ph.D

Theo Melas-Kyriazi

Alan Crane

Polaris Partners

James Gilbert

Flagship Pioneering

Richard Moscicki MD

Other companies like KSQ Therapeutics in the Healthcare sector

Neuralink

Sector

Healthcare

Last Round Est. Valuation

$2.15B

Sector

Sector

Last Round Est. Valuation

$3.67B

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Grail

Sector

Healthcare

Last Round Est. Valuation

$4.26B

Sector

Sector

Sector

Last Round Est. Valuation

$1.08B

Precision Neuroscience

Sector

Healthcare

News

Business Wire 11/12/2019

KSQ Therapeutics Enhances Board of Directors with Two Appointments

KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of

Popular Topics

Popular Topics

KSQ Therapeutics Stock

Register for Details